Public health and valorization of genome-based technologies: A new model

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Lal, Jonathan A ^a   Schulte in den Bäumen, Tobias ^a   Morré, Servaas A ^a,b   Brand, Angela ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Genomics; Health impact assessment; Health needs assessment; Health policy; Health technology assessment; Healthcare; Public health genomics; Technology transfer; Translational research; Valorization

Indexed keywords

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CONSULTATION; GENE TECHNOLOGY; GENETIC MODEL; HEALTH CARE NEED; INTEGRATED HEALTH CARE SYSTEM; KNOWLEDGE BASE; NEEDS ASSESSMENT; NETWORK LEARNING; PROCESS DESIGN; PROCESS OPTIMIZATION; PUBLIC HEALTH SERVICE; PUBLIC-PRIVATE PARTNERSHIP; GENOMICS; HUMAN; MEDICAL TECHNOLOGY; METHODOLOGY; PUBLIC HEALTH; THEORETICAL MODEL;

BIOMEDICAL TECHNOLOGY; GENOMICS; HUMANS; MODELS, THEORETICAL; PUBLIC HEALTH; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 82655183772     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-207     Document Type: Article

References (52)

1. Business Insights: Trends in Biotechnology Technology Transfer to 2014-Deal volume has doubled since 2008. , http://www.reports-research.com/168/d/2011/02/14/business-insights-trends-in-biotechnology-technology-transfer-to-2014-deal-volume-has-doubled-sin/
2. Byrd CA. Profile of Spin-off Firms in the Biotechnology Sector: Results from the Biotechnology use and Development Survey-1999. Business Special Surveys and Technology Statistics Division Working Papers 2002, Statistics Canada.
3. Strength and Opportunity The landscape of the medical technology, medical biotechnology and industrial biotechnology sectors in the UK. 2009, 11-12. HM Government, 28, 34, 38, 40.
4. Maggon K. Global Biotechnology Market Intelligence Monograph. 2011, Knol Publishing Guild, 32.
5. US Biotech Market Analysis. 2010, RNCOS Industry Research Solutions.
6. Bercowitz SF. Biotech made easy. , http://www.mnn.com/green-tech/research-innovations/stories/biotech-made-easy
7. Ukropcova D, Sturdik E. Biotechnology commercialization in the world. Acta Chimica Slovava 2011, 4:115-125.
8. Niosi J, Banik M. The evolution and performance of biotechnology regional systems of innovations. Cambridge Journal of Economics 2005, 29:343-357.
9. Fontanarosa PB, DeAngelis CD. Basic science and translational research in JAMA. JAMA 2002, 287:1728. 10.1001/jama.287.13.1728, 11926900.
10. Berwick DM. Disseminating Innovations in Health Care. JAMA 2003, 289:1969-1970. 10.1001/jama.289.15.1969, 12697800.
11. Peng W. Trends in the biotech literature 2009. Nature Biotechnology 2010, 28:887. 10.1038/nbt0910-887, 20829818.
12. Snyder M, Cook-Deegan B. DNA Patent Database Statistics: 2010. 2011, DNA Patent Database.
13. Catalogue of Biotechnology Patents in the Mercosur. 2008, BIOTECHSUR.
14. Murtagh J, Foerster V. Managing Technology Diffusion-Discussion Paper. 2009, 4. Canadian Agency for Drugs and Technologies in Health, 7-8, 10.
15. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention. Genetics in Medicine 2007, 9:665. 10.1097/GIM.0b013e31815699d0, 18073579.
16. Copple RF, Wellons HB. Evolution of a Bio-Product. Corporate Counsel 2008, 65-66.
17. Mullins B, Crowe J. Technology Transfer: A Roadmap. College and University Auditor 1999,
18. Outreach & Tech Transfer. , http://www.ncat.edu/~divofres/ott/howto.php
19. Rasmussen E. The Process of New Venture Creation in a University Setting. Accompanying measures & survival of new firms: between Darwinism and assistance 2005, Montpellier.
20. Rosenköetter N, Vondeling H, Blancquaert I, Mekel OCL, Kristensen FB, Brand A. The Contribution of Health Technology Assessment, Health Needs Assessment, and Health Impact Assessment to the Assessment and Translation of Technologies in the Field of Public Health Genomics. Public Health Genomics 2011, 14:46-47.
21. HTA Definition. , http://www.eunethta.eu/Public/About_EUnetHTA/HTA/
22. Health Impact Assessment: Main concepts and suggested approach Gottenburg consensus paper. 1999, 4. Brussels: European Center for Health Policy.
23. Crow MM, Tucker C. The American research university system as America's de facto technology policy. Science and Public Policy 2001, 28:2-9.
24. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA. The quality of health care delivered to adults in the United States. New England Journal of Medicine 2003, 348:2643-2644.
25. Woolf SH. The Meaning of Translational Research and Why It Matters. JAMA 2008, 299:211-213. 10.1001/jama.2007.26, 18182604.
26. Williams A. Priority setting in public and private health care. A guide through the ideological jungle. Journal of Health Economics 1988, 7:173-183. 10.1016/0167-6296(88)90015-X, 10288957.
27. Ostrower F. Foundation Effectiveness Definitions and Challenges. 2004, 6. The Urban Institute.
28. Managing Clinical Effectiveness Definition. , http://www.clinicalgovernance.scot.nhs.uk/section2/definition.asp
29. Burke W, Khoury MJ, Stewart A, Zimmern RL. The path from genome-based research to population health: Development of an international public health genomics network. Genetics in Medicine 2006, 8:453.
30. Valorize. , http://www.merriam-webster.com/dictionary/valorize
31. Wiedhaup K, Herben C, Meijer I. Diversity. Partners in the polder A vision for the life sciences in the Netherlands and the role of public-private partnerships 2009, 221. Roland Berger Strategy Consultants, Laane C, Besteman K.
32. Innovation Roadmap on Bio-based Feedstocks, Fuels and Industrial Products. 2003, Bioproducts Canada.
33. Traore N. Bioproducts development by Canadian biotechnology firms: findings from the 2001 Biotechnology use and development Survey. 2003, Statistics Canada.
34. Progress report#1-Bioresources Final Research to Support Development of an Organization to Advance and Promote British Columbia's Bioproducts Industry. 2005,
35. Roozenburg N, Eekels J. The Basic Design Cycle. Product Design: Fundamentals and Methods 1995, 84-93.
36. The Fish Trap Model. Delft Design Guide 2001, Delft: Faculty of Industrial Design, van Boeijen A, Daalhuizen J.
37. Health Technology Assessment Process. , http://www.cgh.uottawa.ca/WHOCC/projects/eo_toolkit/hta.htm
38. The HTA process of DAHTA@DIMDI. , http://web.archive.org/web/20090626065707/http://www.dimdi.de/static/en/hta/methoden/prozess/index.htm
39. Douw K, Vondeling H, Eskildsen D, Simpson S. Use of the Internet in Scanning the Horizon for New and Emerging Health Technologies: A Survey of Agencies Involved in Horizon Scanning. Journal of Medical Internet Research 2003, 5.
40. Brown IT, Smale A, Verma A, Momandwall S. Medical technology horizon scanning. Australasian Physical & Engineering Sciences in Medicine 2005, 28:200-201. 10.1007/BF03178717, 21949929.
41. Sarewitz D, Pielke RA. The neglected heart of science policy: reconciling supply of and demand for science. Environmental Science & Policy 2007, 5-14.
42. Beskow LM, Khoury MJ, Baker TG, Thrasher JF. The integration of Genomics into public health research, policy and practice in the United States. Community Genetics 2001, 4:4.
43. Oestreich T. The value of information Part 1-The Framework. Journal of Management Excellence: The Value of Information 2010, 8-9.
44. Martin MJC. Innovations as Technological Mutations. Managing innovation and entrepreneurship in technology-based firms 1994, 43. John Wiley & Sons Inc..
45. Laane C, Besteman K, Dongen B, Vugts J. Unity. Partners in the polder A vision for the life sciences in the Netherlands and the role of public-private partnerships 2009, Roland Berger Strategy Consultants, Laane C, Besteman K, 18, 39, 40.
46. Tijssen RJW. Quantitative assessment of large heterogeneous R&D Networks: The case of process engineering in the Netherlands. Research policy 1998, 26:792.
47. Fischer MM, Fröhlich J, Gassler H, Varga A. Innovation, Knowledge Creation and Systems of Innovations. ERSA conference papers 2000, 5-7.
48. Cohen WM, Levinthal DA. Innovation and Learning: The two faces of R & D. The Economic Journal 1989, 99:569-570.
49. Booth-Clibborn N, Packer C, Stevens A. Health technology diffusion rates. Statins, coronary stents, and MRI in England. International Journal of Technology Assessment in Health Care 2000, 16:781-786. 10.1017/S0266462300102053, 11028133.
50. EUnetHTA WP4-Core HTA on Drug Eluting Stents. 2008, Pilot assessment European Network for Health Technology Assessment.
51. Becla L, Lunshof JE, Gurwitz D, Schulte in den Bäumen T, Westerhoff HV, Lange BM, Brand A. Health technology assessment in the era of personalized health care. International Journal of Technology Assessment in Health Care 2011, 27:118-126. 10.1017/S026646231100002X, 21450126.
52. Clinical Utility of Personalised Medicine. 2011, 3. National Health and Medical Research Council.